Supplier Selection · IVD & Cell Culture

Switching Human Serum Supplier — The 7 Criteria That Actually Matter

Whether you are moving to a new supplier because of supply issues, documentation gaps, pricing or regulatory requirements — switching human serum is not a decision to take lightly. This guide covers the seven criteria that experienced IVD developers and cell culture teams use to evaluate and qualify a new human serum supplier.

The 7 Criteria for Evaluating a Human Serum Supplier

1

Donor Origin & Regulatory Framework

For European IVD manufacturers under EU IVDR 2017/746, the donor origin directly affects your regulatory documentation. EU-qualified donors processed under EU Blood Directive 2002/98/EC give you the cleanest path through your technical file. US-origin material is not disqualified — but it requires additional justification in a European regulatory submission.

Ask your supplier: "What country are your donors from and under which regulatory framework are they qualified?"
2

Donor Screening Panel

Minimum screening for human serum should include HIV 1/2 (antibody and NAT), HBsAg, anti-HCV (and HCV RNA), syphilis and HTLV I/II where applicable. For IVD applications, request the full screening certificate — not just a COA summary. Extended panels (HAV, HEV, B19 parvovirus) are relevant for specific assay types.

Ask your supplier: "Can you provide the full donor screening panel with NAT results for each lot?"
3

Lot-to-Lot Consistency & Batch Reservation

Human serum is a biological material — inherent lot variability is unavoidable. The question is how your supplier manages it. Batch reservation — the ability to reserve a validated lot and call it off over time — is the single most important operational tool for managing consistency in long-term projects. Many suppliers offer it in principle but restrict it by volume minimums or prepayment requirements.

Ask your supplier: "Can I reserve a specific lot without prepayment and call it off in partial deliveries?"
4

Documentation Quality

A COA is the minimum. For IVD development and GMP applications, you also need: origin certificate, donor screening records, sterility test results, processing batch records and ideally a technical file or DMF number for regulatory submissions. Suppliers that cannot provide this documentation within 48 hours are a red flag for any regulated application.

Ask your supplier: "What documentation do you supply per lot, and what is available on request?"
5

Processing Options & Variants

Native, heat inactivated, delipidated, IgG-depleted, charcoal stripped, gamma irradiated — the range of processing options determines whether a supplier can serve your full application portfolio or only part of it. Sourcing multiple human serum variants from a single supplier reduces qualification burden significantly.

Ask your supplier: "Which processing variants do you have in stock vs. available on request, and what are the lead times?"
6

Volume Flexibility & Minimum Orders

Development teams need small quantities for method development and validation. Production teams need reliable large-volume supply. A supplier that requires large minimum orders for development quantities forces you into either overstocking or sourcing from multiple suppliers. No minimum order quantity with flexible volume options is the ideal setup for both phases.

Ask your supplier: "What is the minimum order quantity, and can I order 100 ml for initial validation?"
7

Supply Security & Lead Times

Human serum supply is inherently dependent on donor availability. Supply disruptions are more common than most labs anticipate — particularly for rare formats like delipidated, IgG-free or male-only serum. A supplier with EU stock, short lead times and a clear batch reservation policy significantly reduces your supply chain risk compared to a supplier shipping from overseas or operating on order-only basis.

Ask your supplier: "Where is the stock held, what are typical lead times, and what happens if my reserved lot runs out?"

Supplier Switching Checklist — Before You Commit

Request test samples of at least 2 different lots — not just 1. Single-lot evaluation does not reveal batch variability.

Run a parallelism study — test new supplier lot against your current validated lot side-by-side in your assay or cell culture system.

Define acceptance criteria before testing — not after. Minimum cell growth %, maximum CV between lots, minimum analyte recovery in your assay.

Request full documentation upfront — COA, donor screening, origin certificate. If the supplier hesitates, that tells you something.

Clarify batch reservation terms — volume, timeline, prepayment requirements, what happens if the reserved lot is exhausted.

Overlap your supply — maintain sufficient stock of the old lot during validation of the new lot. Never switch in the middle of a project without a validated alternative.

Document the switch — for GMP and IVD applications, a supplier change is a documented change control event. Prepare your comparability report before initiating the switch.

Which Criteria Matter Most — By Application

Application Most Critical Criteria Key Format
CAR-T / ATMP manufacturing EU origin, GMP documentation, lot reservation, xeno-free Human Serum AB, native or HI
IVD assay development Donor screening documentation, lot consistency, matrix matching Universal Negative, Delipidated
Lipemia interference studies Delipidation method, residual lipid specification, CLSI EP7 Delipidated (SP1010)
Hormone / steroid assays Charcoal stripping completeness, hormone-free certificate Double Charcoal Treated (F12010)
Malaria / P. falciparum culture Type AB mandatory, lot qualification by parasitaemia assay Human Serum AB, off-the-clot
Hybridoma production Complement inactivation, IgG background level Heat Inactivated, Type AB
MSC expansion (clinical) Xeno-free, EU origin, GMP documentation, lot reservation Human Serum AB or HPL
IVDR note: Under EU IVDR 2017/746, switching human serum in a registered IVD product requires a change notification and updated technical documentation. Plan your switching study to generate the comparability data required before filing the change.

Why labs switch to SeamlessBio for human serum

  • EU-qualified donors — processed under EU Blood Directive 2002/98/EC, directly relevant for IVDR technical documentation
  • Batch reservation without prepayment — reserve your validated lot, call off in partial deliveries as needed
  • No minimum order quantity — 100 ml for validation, bulk for production — same supplier, same lot
  • Full documentation — COA, donor screening records, origin certificate on every lot
  • Full portfolio — native, heat inactivated, delipidated, IgG-free, charcoal treated, universal negative, HPL — all from EU donors
  • Direct contact — personal support from Passau, no call centre, no ticket system

SeamlessBio Human Serum Portfolio

All variants available from EU stock — test samples on request, batch reservation without prepayment, no minimum order quantity.

Frequently Asked Questions

How long does a human serum supplier switching study typically take?

For cell culture applications, a typical switching study takes 3–6 weeks: 1–2 weeks for parallel culture comparison, 2–3 weeks for functional assay validation and data review. For IVD applications under IVDR, the formal comparability study and change documentation can take 6–12 weeks depending on your internal change control process. We recommend requesting test samples from at least 2 different SeamlessBio lots to include inter-lot variability in your evaluation.

Can I test SeamlessBio human serum against my current supplier before committing?

Yes — free test samples are available for all human serum variants. Contact us at info@seamlessbio.de or +49 851 37932226. We recommend testing at least two lots side-by-side against your current reference. Batch reservation is available without prepayment once you have completed your switching study.

What documentation does SeamlessBio provide for IVDR technical files?

For each lot we supply: Certificate of Analysis (COA), donor screening records (HIV 1/2, HBsAg, HCV, syphilis — with NAT results), origin certificate confirming EU donor qualification under EU Blood Directive 2002/98/EC, sterility test results and processing documentation. Extended documentation for GMP or IVDR submissions is available on request — contact info@seamlessbio.de with your specific requirements.

Is batch reservation available without minimum order quantities?

Yes — SeamlessBio offers batch reservation for all human serum products without prepayment and without minimum order quantity. Once you have validated a lot in your system, we hold it in EU stock and release volumes as you need them. This applies from 100 ml development quantities through to multi-litre production volumes.

What is the difference between off-the-clot and converted human serum?

Off-the-clot serum is produced by allowing blood to clot naturally without additives — the resulting serum retains the natural protein composition and complement activity. Converted serum is produced from plasma by adding calcium chloride or thrombin to induce clotting. The protein composition is similar but converted serum may have slightly different growth factor profiles. For most cell culture applications, both are equivalent. For applications sensitive to fibrin or clotting factor residuals, off-the-clot is preferred.

Ready to evaluate SeamlessBio human serum?

Free test samples, no minimum order, batch reservation without prepayment. EU stock in Passau — fast delivery across the EU and UK.